The Special Purpose Acquisition Companies and Life Sciences teams advised Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) in its definitive business combination agreement with Humacyte, Inc. and related $175 million PIPE financing. A group of top-tier healthcare investors has committed to participate the PIPE financing that will close simultaneously with the business combination. The combined company will also receive up to $100 million held in AHAC’s trust account at closing of the transaction, subject to any redemptions by existing AHAC shareholders.
Upon closing of the transaction, AHAC will be renamed Humacyte, Inc. The combined company’s common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol “HUMA.”
Alpha Healthcare Acquisition Corp. is a special purpose acquisition company formed for the purpose of effecting a business combination with one or more businesses in the healthcare sector. AHAC was founded by Mr. Rajiv Shukla, who has two decades of buyouts, investments and operations experience in the healthcare industry.
Humacyte, Inc. is developing a disruptive technology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. Humacyte develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s innovative technology has the potential to support tissue repair, reconstruction and replacement without the limitations of existing standards of care. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease.
The Goodwin team was led by Mike Patrone and Laurie Burlingame, with invaluable assistance from Jocelyn Arel and Tom Levato, and included Julie Tibbets, Alexandra Denniston, Roger Cohen, Suhrid Wadekar, Jennifer Fay, Jacqueline Klosek and Janet Andolina.
For additional details on the transaction, please read the press release.